uniQure (NASDAQ:QURE) Receives $38.89 Consensus PT from Brokerages

Shares of uniQure (NASDAQ:QURE) have been given a consensus rating of “Moderate Buy” by the ten research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $38.89.

QURE has been the topic of a number of recent research reports. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Stifel Nicolaus upped their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Leerink Partners lifted their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $10.60 on Tuesday. The business’s 50-day simple moving average is $13.70 and its 200 day simple moving average is $10.86. The company has a market cap of $573.22 million, a P/E ratio of -2.14 and a beta of 0.36. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a one year low of $3.73 and a one year high of $19.18.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 over the last ninety days. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

Several hedge funds have recently made changes to their positions in the stock. RTW Investments LP bought a new position in uniQure during the 3rd quarter worth $49,000. Atria Investments Inc bought a new position in shares of uniQure during the third quarter worth about $53,000. Quarry LP bought a new position in shares of uniQure during the third quarter worth about $58,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure in the 3rd quarter worth about $69,000. Finally, Twin Tree Management LP bought a new stake in uniQure in the 4th quarter valued at about $77,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.